IL Therapeutics
Industry | Biotechnology |
---|---|
Headquarters | 105E ñ 111 Research Drive, Saskatoon, SK, Canada |
IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP ("Western Life Sciences") and in 2006 its shares were purchased by Pacgen Biopharmaceuticals Corporation ("Pacgen").[1][2]
History
[edit]Saskatchewan Research Council operates a bioprocessing laboratory which facilitated biomedical research. IL Therapeutics was developed from research first begun at the Western College of Veterinary Medicine.
Pharmaceuticals
[edit]Currently IL Therapeutics is working on a drug candidate, IL-8(3-73)K11R/G31P ("PAC-G31P") for relief of Acute Respiratory Distress Syndrome (ARDS).[1] The Saskatchewan Research council, SRC also assisted with the funding of this project through the Agriculture Development Fund - SRC Industry Venture Fund.[3] With the successful progression of G31P, the University of Saskatchewan Industry Liaison Office (ILO) decided to commercialize a commercialize this new drug treatment.[4] This research has been sponsored by a $3 million boost from the Western Life Sciences Venture Fund (WLS)[5]
See also
[edit]- Biotechnology
- List of biotechnology companies
- Innovation Place Research Park
- University of Saskatchewan
References
[edit]- ^ a b "Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc" (PDF) (Press release). Pacgen Biopharmaceuticals. April 12, 2006. Archived from the original (PDF) on July 15, 2011. Retrieved August 11, 2018.
- ^ "Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc". Pacgen Biopharmaceuticals. April 12, 2006. Retrieved August 11, 2018.
- ^ Saskatchewan Research Council 2005-2006 Annual Report. Sustainable Science Solutions. pp. 7–8. Archived from the original on July 6, 2011. Retrieved August 11, 2018.
{{cite book}}
: CS1 maint: numeric names: authors list (link) - ^ U of S News Releases: University Communication, U of S News Releases: U of S Signs Letter of Intent to Commercialize Treatment for Lung Injury Complications, archived from the original on 2011-07-06, retrieved Sep 9, 2007
- ^ "U of S News Releases: U of S Spin-off gets $3 Million Boost to Develop Anti-inflammatory Drug" (PDF). Business View. Saskatoon and District Chamber of Commerce: 3. December 2004. Retrieved August 11, 2018.